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Abstract
Aims: TCF7L2 variants have been associated with type 2 diabetes, body mass index (BMI), and deficits in proinsulin
processing and insulin secretion. Here we sought to test whether these effects were apparent in high-risk individuals and
modify treatment responses.
Methods: We examined the potential role of the TCF7L2 rs7903146 variant in predicting resistance to weight loss or a lack of
improvement of proinsulin processing during 2.5-years of follow-up participants (N=2,994) from the Diabetes Prevention
Program (DPP), a randomized controlled trial designed to prevent or delay diabetes in high-risk adults.
Results: We observed no difference in the degree of weight loss by rs7903146 genotypes. However, the T allele (conferring
higher risk of diabetes) at rs7903146 was associated with higher fasting proinsulin at baseline (P,0.001), higher baseline
proinsulin:insulin ratio (p,0.0001) and increased proinsulin:insulin ratio over a median of 2.5 years of follow-up (P=0.003).
Effects were comparable across treatment arms.
Conclusions: The combination of a lack of impact of the TCF7L2 genotypes on the ability to lose weight, but the presence of
a consistent effect on the proinsulin:insulin ratio over the course of DPP, suggests that high-risk genotype carriers at this
locus can successfully lose weight to counter diabetes risk despite persistent deficits in insulin production.
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It is well established that the rs7903146 variant in the
transcription factor 7-like 2 gene (TCF7L2) is associated with type
2 diabetes (T2D) [1–4]. The TT genotype at rs7903146 also
predicted progression to diabetes in the Diabetes Prevention
Program (DPP) [5] and the Finnish Diabetes Prevention Study [6].
The extent to which rs7903146 may also be associated with
body mass index (BMI) and ability to lose weight remains
controversial. Helgason and colleagues [7] reported that a
haplotype including the C allele at rs7903146 and the A allele at
rs10885406 (HapA) was positively associated with BMI, whereas
the absence of HapA (noted as HapB) including the diabetes risk T
allele at rs7903146 was negatively associated with BMI. The
negative association between the diabetes risk T allele at
rs7903146 and BMI was also observed in DPP at baseline [5].
However, no direct effect of the T allele on BMI has been seen in
population-based samples [8,9].
Two studies that have evaluated whether rs7903146 alters
weight loss response to behavioral intervention have had differing
outcomes. Cauchi et al. documented a lack of impact of rs7903146
on the extent of weight loss in response to a 10-week hypocaloric
diet [8]. However, Haupt et al. found that carriers of the T allele
at rs7903146 lost less weight in response to an exercise and dietary
intervention than CC homozygotes [10], suggesting a potential
link between TCF7L2 and resistance to weight loss.
Table 1. Demographic characteristics and baseline and change in weight, proinsulin, insulin and proinsulin:insulin ratio over 2.5
year follow-up.
Treatment Group
Placebo Metformin Lifestyle
Baseline
N 1000 990 1004
Male 311 (31.1%) 344 (34.7%) 327 (32.6%)
Age (yr) 50.5610.5 51.0610.4 50.7611.4
Self-reported ethnicity
Caucasian 557 (55.7%) 570 (57.6%) 547 (54.5%)
African American 210 (21.0%) 206 (20.8%) 196 (19.5%)
Hispanic 164 (16.4%) 158 (16.0%) 176 (17.5%)
Asian/Pacific Islander 39 ( 3.9%) 33 ( 3.3%) 56 ( 5.6%)
American Indian 30 ( 3.0%) 23 ( 2.3%) 29 ( 2.9%)
rs7903146
C C 509 (51.2%) 447 (45.3%) 513 (51.2%)
C T 404 (40.6%) 447 (45.3%) 376 (37.5%)
T T 82 ( 8.2%) 92 ( 9.3%) 113 (11.3%)
HapA
a
PP 285 (28.5) 239 (24.1) 276 (27.5)
AP 441 (44.1) 451 (45.6) 413 (41.1)
AA 274 (27.4) 300 (30.3) 315 (31.4)
Weight (kg) 94.8620.2 94.6620.0 94.5620.8
BMI (kg/m
2)3 4 . 3 66.7 34.066.7 34.066.8
Waist (cm) 105614.5 105614.5 105614.9
Glucose (mg/dL) 107.068.4 106.768.4 106.567.9
Median (min,max) Median (min,max) Median (min,max)
Proinsulin (pM) 14 (3 to 144) 14 (2 to 131) 14 (2 to 120)
Insulin (pmol/L) 167 (21 to 1153) 167 (21 to 722) 167 (17 to 1278)
Proinsulin/insulin ratio (%) 10 (2 to 95) 11 (1 to 97) 11 (2 to 101)
Follow up
b Mean (95% CI) Mean (95% CI) Mean (95% CI) P val*
Change in Weight (kg) 0.95 (0.12–1.78) 20.78 (21.61–0.04) 24.53 (25.36–3.71) ,0.001
Change in Proinsulin (pM) 1.19 (0.52 to 1.86) 22.76 (23.43 to 22.08) 23.30 (23.96 to 22.64) ,0.001
Change in Insulin (pmol/L) 2.40 (1.53 to 3.28) 21.63 (22.52 to 20.737) 22.17 (23.04 to 21.30) ,0.001
Change in Insulin/Proinsulin Ratio (%) 20.25 (20.29 to 0.78) 20.68 (21.2 to 20.13) 20.12 (20.65 to 0.42) ,0.001
*P values from mixed models adjusted for baseline variable, age, self-reported ethnicity and sex.
aP - HapA present; A - HapA absent.
bMedian follow-up 2.5 years.
Statistics shown are number of subjects and percents within each treatment group or means +/2 standard deviation unless noted.
doi:10.1371/journal.pone.0021518.t001
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associated with impaired insulin secretion [5]. Despite active
research on the mechanism by which variation in TCF7L2
increases diabetes risk and affects b-cell function, the precise
mode of action is poorly understood. One hypothesis involves
interference with proinsulin processing. Loos and colleagues
reported a highly significant association of the T allele at
rs7903146 with circulating fasting proinsulin and the proinsuli-
n:insulin ratio in healthy white adults from the United Kingdom
[11]. This association has since been replicated [9,12,13], and
recent animal experimentation suggests that TCF7L2 silencing
may impair insulin vesicle trafficking [14]. The extent to which
rs7903146 may alter the beneficial impact of lifestyle intervention
and metformin on proinsulin:insulin ratio remains to be
determined.
In the present paper, we sought to examine whether rs7903146
and HapA in TCF7L2 are also associated with: 1) resistance to
weight loss; and 2) a lack of improvement in proinsulin:insulin
ratio in over a median of 2.5 year follow-up in DPP.
Materials and Methods
Ethics Statement
The Office of Human Research at The George Washington
University Medical Center is the institutional review board
responsible for insuring that The Biostatistics Center adheres to
the principles expressed in the Declaration of Helsinki in approving
the coordination, research, and analysis of data for the Diabetes
Prevention Program (DPP) and Diabetes Prevention Program
Outcomes Study (DPPOS). The participants of the DPP /DPPOS
were not placed at undue risk and have provided written informed
consent for their participation in all aspects of the study protocol.
The consents obtained from participants at individual DPP clinics
were approved by that clinic’s institutional review board.
Sample
The DPP [15,16] enrolled 3,234 participants at high risk of
developing diabetes (on the basis of increased fasting glucose,
impaired glucose tolerance, and a BMI of 24 or higher) across 27
clinical centers throughout the U.S. Participants were randomized
to placebo, metformin 850 mg twice daily or a lifestyle intervention
aiming at $7% weight loss and $150 minutes of physical activity
per week. The average weight loss was 0.1, 2.1 and 5.6 kg in the
placebo, metformin and lifestyle interventions, respectively, during
a median of 2.5 years follow-up (median=2.5 years, range 0.5–5.0
years). The 2,994 participants presented in this paper provided
informed consent specifically for genetic analyses.
Height and Weight
Standing height was determined in duplicate at baseline using a
calibrated stadiometer. Weight was measured in duplicate on a
calibrated balance beam scale semi-annually.
Proinsulin and insulin
Fasting blood was drawn annually for measurements of insulin
and proinsulin. Insulin measurements were performed using a
radioimmunoassay method incorporating an anti–guinea pig
antibody that measures total immunoreactive insulin. The assay
is a 48-h polyethylene glycol–accelerated method with coefficients
of variation (CVs.) of 4.5% for high-concentration quality control
samples and 6.9% for low-concentration quality control samples.
The CV for masked split duplicates in this assay was 8.5%.
Proinsulin was measured by a commercially available radioim-
munoassay method (Linco Research, St. Louis, MO) [15].
Genotyping
Genotyping was performed by allele-specific primer extension of
multiplex amplified products and detection using matrix-assisted
laser desorption ionization-time-of-flight mass spectrometry on a
Sequenom iPLEX platform [17] as previously described [5]. The
rs7903146, rs10885406 and rs7924080 SNPs were selected based
on prior association with diabetes and/or BMI [4,5]. Hardy-
Weinberg equilibrium was observed for the SNPs in all major
race/ethnic groups.
As noted by Helgason et al., [4] HapA can be tagged by the
combination of the A allele at rs10885406 and the C allele at
rs7903146, or by the T allele at rs7924080; for the purposes of this
manuscript, we used the first definition. Haplotypes were
determined within each self-reported ethnic group by using the
expectation-maximization algorithm of Excoffier and Slatkin [18]
modified to process larger data files using the partition-ligation
approach. We confirmed that HapA defined by rs10885406 and
rs7903146 is highly correlated with rs7924080 in our dataset, with
r
2=0.98 in whites, 0.97 in African Americans, 0.99 in Hispanics,
0.91 in Asians and 1.0 in Native Americans.
Statistical analysis
The primary analyses involved testing whether weight,
proinsulin:insulin ratio, and the numerator and denominator of
the ratio, proinsulin and insulin, differed by genotype at rs7903146
or HapA at baseline and over a median of 2.5 year follow-up. We
used analyses of covariance with a genotypic model to test baseline
differences in weight and natural log transformed proinsulin,
insulin and proinsulin:insulin ratio. Age, sex, ethnicity were
statistically adjusted in tests for baseline weight. BMI and
Figure 1. Mean weight loss in the Diabetes Prevention Program by treatment group and genotype at rs7903146.
doi:10.1371/journal.pone.0021518.g001
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concentrations, were also statistically adjusted in baseline models
for proinsulin, insulin and proinsulin:insulin ratio.
General linear models for fixed effects were used to test the
relationship between the TCF7L2 variants and longitudinal change
in weight, proinsulin, insulin and proinsulin:insulin ratio over 2.5
years of follow-up. All longitudinal models were adjusted by age,
sex, ethnicity, and the corresponding baseline parameter. Analyses
of proinsulin, insulin and proinsulin:insulin ratio were further
adjusted for baseline BMI and fasting glucose. In each analysis a
genotype6treatment arm interaction was included. Nominal two-
sided Pvaluesarereportedadjustedformultiplecomparisonswithin
each genotype using the Holm procedure [19]. All analyses were
conducted in SAS, version 9.1 (SAS Institute, Inc, Cary, NC).
Results
Demographic characteristics, baseline anthropometric charac-
teristics and baseline proinsulin and insulin levels and proinsuli-
n:insulin ratios are presented in Table 1. No significant differences
between treatment arms were observed at baseline. At follow-up,
the treatment arms differed significantly in weight loss, proinsulin
and insulin concentrations and proinsulin:insulin ratio.
Weight loss
As previously reported, the T allele at rs7903146 was associated
with a lower BMI at baseline (P,0.01). No differences in baseline
c a l o r i ci n t a k eo rp h y s i c a la c t i v i t yb yg e n o t y p ew e r eo b s e r v e d( P=0.70
and 0.23, respectively), suggesting that these measures did not account
for the association of rs7903146 with baseline BMI. No association
between HapA and BMI was seen in this cohort (P=0.32).
Weight loss by rs7903146 is presented in Figure 1. There were
no differences in the degree of weight loss by genotype at
rs7903146 (P=0.95) with no significant interaction of genotype
with treatment arm (P=0.82). Similarly, there were also no
differences in the degree of weight loss by haplotype at HapA
(P=0.99), with no interaction of haplotype with treatment arm
(P=0.28).
Proinsulin, insulin and proinsulin:insulin ratio
Proinsulin, insulin and proinsulin:insulin ratio at baseline and
change in these parameters over a median of 2.5 year follow up
are presented in Table 2. Genotypes at rs7903146 were not
significantly associated with fasting proinsulin at baseline or over
2.5 year follow-up. No interactions with treatment arm were
observed.
The rs7903146 SNP was significantly associated with fasting
insulin at baseline. The TT genotype at rs7903146 was associated
with the lowest insulin level, differing significantly from CC
genotypes. CT genotypes also exhibited lower fasting insulin than
CC genotypes. Once baseline levels were statistically controlled,
no differences in the change in insulin level by rs7903146 were
observed over 2.5 year follow-up and no interactions with
treatment arm were observed.
The rs7903146 SNP was also significantly associated with the
proinsulin:insulin ratio at baseline. At baseline, the TT genotype at
rs7903146 was associated with the highest proinsulin:insulin ratio,
differing significantly from CC genotypes and tending to differ
from CT genotypes. The CT genotype was also associated with a
higher proinsulin:insulin ratio than the CC genotype. Genotype at
rs7903146 was also significantly associated with change in
proinsulin: insulin ratio over the median of 2.5-year follow up
once baseline levels were statistically controlled. Carriers of CC
genotypes showed a decline in proinsulin:insulin ratio across the
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who experienced an increase. No heterogeneity in these effects by
treatment group was observed. Mean change in proinsulin:insulin
ratio over the course of the study by rs7903146 are presented in
Figure 2.
The absence of HapA was significantly associated with lower
insulin (P=0.04) and greater proinsulin:insulin ratio at baseline
(P=0.01) at baseline. The absence of HapA was also associated
with a blunted decline in proinsulin:insulin ratio over 2.5 year
follow-up (P=0.04). In order to distinguish whether the associa-
tion signal was due to rs7903146 or HapA (which are highly
correlated), we performed stratified analyses of the association of
one variant with proinsulin:insulin ratio within each genotypic
group for the other. The only significant association in these
stratified analyses was found for the T allele at rs7903146 within
HapA heterozygotes (P,0.001), suggesting that the association is
driven by rs7903146 and not HapA.
Discussion
The results of this study indicate that the variation in the
TCF7L2 gene previously associated with T2D and BMI does not
predict ability to lose weight. This effect was consistent across
those randomized to the intensive lifestyle, metformin treatment,
or placebo interventions, indicating that the extent and mode of
weight loss do not influence the genetic associations. However, the
T allele at rs7903146 was associated with higher proinsulin:insulin
ratio at baseline and, once baseline values were statistically
adjusted for, change in the proinsulin:insulin ratio over a median
of 2.5 year follow-up. This effect was consistent across treatment
arms in DPP despite significant weight losses in the lifestyle and
metformin groups, relative to the placebo group.
As new genetic associations with T2D continue to emerge, it is
plausible that genetic information may be used to guide the choice
of preventive interventions. Before this can be achieved, it will be
important to document the potential impact of these diabetes risk
loci on the effectiveness of both pharmacological and behavioral
interventions. For example, the extent of weight loss in response to
a standardized caloric restriction regimen is highly heritable in
twin studies [20]. Genetic loci previously associated with T2D or
obesity serve as leading candidates that may promote resistance to
weight loss in response to a behavioral intervention. In the current
paper, we find that the diabetes risk marker rs7903146 in TCF7L2
does not impact the ability to lose weight in response to metformin
or behavioral intervention. This is consistent with one prior paper
reporting no association of rs7903146 with the extent of weight
loss in response to a short-term hypocaloric diet [8]. However,
were unable to replicate a second paper from the Tuebingen
Lifestyle Intervention Program (TULIP) reporting that carriers of
the T allele showed blunted weight loss in response to a nine-
month combined diet and exercise program [10]. Of relevance to
this report, we found no heterogeneity of effect across treatment
arms, indicating that the effect of genotype did not differ in the
lifestyle intervention arm, relative to the metformin or placebo
arms. We also found no heterogeneity by time, indicating that
genotype effects at year 1 did not differ significantly from other
time points. Several potential differences across the studies may
account for the different results, including length of follow-up,
nature or intensity of the lifestyle intervention and the extent of
weight loss achieved. Of note, the TULIP included a dietary fiber
intervention not included in the DPP. Taken together with a
recent report indicating that dietary fiber may alter the association
between TCF7L2 and diabetes [21], it remains possible that
changing certain components of the diet, such as fiber intake, may
alter risks associated with TCF7L2 variants.
This paper also extends prior results examining the impact of
this locus on proinsulin:insulin ratio. A greater proinsulin:insulin
ratio is thought to reflect a deficit in b-cell secretory function and
TCF7L2 appears to play a critical role in b-cell survival and
glucose-stimulated insulin secretion [22]. Greater proinsulin:insu-
lin ratios have consistently been shown among T allele carriers at
rs7903146 but associations with proinsulin level have been less
consistent [9,11–13]. In the present study, we found that
rs7903146 is associated with a lower insulin level and, as a result,
an elevated proinsulin:insulin ratio at baseline. Further, the
elevated proinsulin:insulin ratio persisted over 2.5 years of
follow-up once baseline values were statistically controlled for
and was consistent across treatment arms. Thus, the impact of
genotype on the proinsulin:insulin ratio does not appear to be
altered by metformin or lifestyle intervention. Proinsulin:insulin
ratio decreased in the metformin and lifestyle intervention arms in
line with the expected improvement in proinsulin:insulin ratio with
increased insulin sensitivity. However, the persistence of differ-
ences in proinsulin:insulin ratios across genotypic groups at
TCF7L2 rs7903146, despite interventions shown to significantly
improve insulin sensitivity [23], raises the possibility that this
defect may be caused by a specific effect of TCF7L2 on proinsulin
processing, b-cell proliferation and/or differentiation, or insulin
vesicle trafficking, rather than by the general stress brought on the
b cell by increased insulin demand.
Helgason and colleagues [7] reported that a haplotype including
the C allele at rs7903146 and the A allele at rs10885406 (HapA)
was positively associated with BMI, whereas the absence of HapA
(noted as HapB) including the diabetes risk T allele at rs7903146
was negatively associated with BMI. We found the associations of
Figure 2. Mean change in proinsulin:insulin ratio in the Diabetes Prevention Program by treatment group and genotype at
rs7903146.
doi:10.1371/journal.pone.0021518.g002
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by variation in the component SNP, rs7903146.
Taken together, the combination of a lack of impact of TCF7L2
genotypes on the ability to lose weight in this study, but its
consistent impact on the proinsulin:insulin ratio, suggests that
persons who carry high-risk genotypes at this locus can successfully
lose weight to counter diabetes risk, despite consistent deficits in
proinsulin processing.
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